A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Withdrawn · Phase 2 · NCT06901349
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $546,057
- U.S. investigators named
- 25
- Sites paid
- 28
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Bimagrumab (drug), Tirzepatide (drug), Bimagrumab Placebo (drug), Tirzepatide Placebo (drug)
- Dates
- Started 2025-05-23; completion 2025-06-10
- Results posted
- Not yet
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
From ClinicalTrials.gov, last updated 2025-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $546,057 in research payments for this study in 2025 (45 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert F. Smythe, M.D. Internal Medicine · Yuma, AZ
- Christopher G. Chow, MD Internal Medicine · Northridge, CA
- Bonnie S. Kimmel, M.D. Endocrinology & Diabetes · Walnut Creek, CA
- Joel M. Neutel, MD Legal Medicine (non-physician) · Tustin, CA
- Dung Trinh, MD Internal Medicine · Mission Viejo, CA
- John M. Joyce, M. D. Psychiatry · Jacksonville, FL
- Volrick D. Morrison, D.O. Internal Medicine · North Miami Beach, FL
- Mary H. Quarterman, M.D. Internal Medicine · Orlando, FL
- Maray Rocher, M.D Internal Medicine · Miami, FL
- Tonita R. Washington, FNP-BC Nurse Practitioners · Lawrenceville, GA
- Cindy H. Pau, MD Endocrinology & Diabetes · Honolulu, HI
- Flint R. Packer, D.O. Family Medicine · Idaho Falls, ID
- Gary M. Ullery, D.O. Internal Medicine · Blackfoot, ID
- Renee M. Galen, MD Family Medicine · Newburgh, IN
- Stephen M. Miller JR., M.D. General Surgery · Boston, MA
- Saba S. Sheikh, M.D. Internal Medicine · Columbia, MD
- Michael J. Hafran, M.D. Family Medicine · East Lansing, MI
- Jeffrey A. Potts, MD Internal Medicine · Bay City, MI
- Klara Klein, MD/PHD Endocrinology & Diabetes · Chapel Hill, NC
- Roy C. St John, MD Pulmonology · Columbus, OH
- Sarah E. Land, D.O. Psychiatry · Tulsa, OK
- Martin Basaldua, M.D. Family Medicine · Kingwood, TX
- Prashant G. Koshy, M.D. Endocrinology & Diabetes · Houston, TX
- Dan Lender, MD Endocrinology & Diabetes · Rockwall, TX
- Arun Arora, M.D. Psychiatry · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Deaconess Clinic Inc $70,684
- Flourish Research Acquisition LLC $68,769
- Charter Research LLC $46,008
- C and S Health Center $41,195
- Northwest Clinical Research Center $37,774
- University of North Carolina at Chapel Hill $31,686
- Great Lakes Research Group Inc $28,296
- Velocity Clinical Research Inc $28,273
- Kur Research $26,977
- Sky Clinical Research Network Group $26,775
- Yuma Clinical Trials LLC $23,331
- Activian Clinical Research LLC $22,540
- Remington-Davis, Inc. $22,526
- Clinical Neuroscience Solutions DBA Cns Hlthcare $12,376
- Central State Research $7,831
- $4,656
- Sociedad Espanola De Medicina De La Adolescencia $4,549
- Bingham Memorial Hospital $4,481
- Endocrine Ips PLLC $4,331
- Valley Clinical Trials Inc $4,331
- Excel Medical Clinical Trials, LLC $4,301
- Family First Medical Center $4,251
- Irvine Center for Clinical Research Inc $4,201
- L&c Professional Medical $4,201
- David Fitzpatrick MD DBA E West Med Rsrch $3,130
- Driscoll Childrens Hospital, TX $3,080
- Northwestern University $3,000
- Memorial Research Medical Clinic $1,301
- Dana Farber PArtners Cancer Care Inc $1,201
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.